Loading..

bluebird bio, Inc. (BLUE) Report Analysis

Corporate Events

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russ...

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell Microcap Value Index

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russ...

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 3000E Index

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russ...

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 3000E Value Index

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russ...

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell Microcap Index

Negative

bluebird bio, Inc. has filed a Follow-on Equity...

2022-06-22 00:00:00

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common S...

Negative

bluebird bio, Inc.(NasdaqGS:BLUE) dropped from ...

2022-06-11 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P Biotechnology Select Industry Index

Positive

bluebird bio, Inc. Announces That the U.S. Food...

2022-06-10 10:03:00

On June 9, 2022, bluebird bio, Inc. ('bluebird' or the 'Company') announced that the U.S. Food and Drug Administration's (FDA) Cellular, Tissu...

Positive

FDA Advisory Committee Unanimously Endorses eli...

2022-06-09 22:14:00

bluebird bio, Inc. announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Commit...

Neutral

bluebird bio, Inc. Presents at RBC Capital Mark...

2022-05-10 10:23:00

bluebird bio, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 08:00 AM. Venue: InterContinental New York, Barcl...

Neutral

bluebird bio, Inc. Presents at Goldman Sachs 43...

2022-05-10 10:23:00

bluebird bio, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 04:00 PM. Venue: Terranea Resort, Rancho Pa...

Neutral

bluebird bio, Inc., Annual General Meeting, Jun...

2022-05-02 21:38:00

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022, at 08:30 Eastern Daylight. Location: 455 Grand Union Boulevard Somerville Massachuse...

Negative

bluebird bio, Inc. Appoints Jason F. Cole as Pr...

2022-05-02 20:06:00

On April 27, 2022, the board of the directors of bluebird bio, Inc. appointed Jason F. Cole, as the Company's principal accounting officer in ...

Neutral

bluebird bio, Inc. Presents at Cell & Gene Meet...

2022-04-17 03:23:00

bluebird bio, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022 . Venue: Barcelona, Spain.

Neutral

Hanson Wade Limited, Gene Therapy Analytical De...

2022-04-06 17:15:00

Hanson Wade Limited, Gene Therapy Analytical Development Europe, May 30, 2022 through Jun 01, 2022. Venue: London, United Kingdom.

Neutral

bluebird bio, Inc. Presents at Gene Therapy Ana...

2022-04-06 17:15:00

bluebird bio, Inc. Presents at Gene Therapy Analytical Development Europe, Jun-01-2022 02:00 PM. Venue: London, United Kingdom. Speakers: Ilya...

Neutral

Hanson Wade Limited, 2nd Annual Gene Therapy Pa...

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022. Venue: Boston, Massachusetts, Unit...

Neutral

bluebird bio, Inc. Presents at 2nd Annual Gene ...

2022-04-06 17:15:00

bluebird bio, Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022 . Venue: Boston, Massachusetts, United States. S...

Neutral

bluebird bio, Inc. - Shareholder/Analyst Call

2022-04-05 11:00:00

bluebird bio, Inc. - Shareholder/Analyst Call

Neutral

bluebird bio, Inc. Presents at Pharma Manufactu...

2022-03-29 08:36:00

bluebird bio, Inc. Presents at Pharma Manufacturing World Summit, Mar-29-2022 . Venue: Boston Marriott Copley Place, Boston, Massachusetts, Un...

Neutral

bluebird bio, Inc. Presents at Bank of America ...

2022-03-22 05:03:00

bluebird bio, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 03:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, ...

Neutral

Executive Platforms Inc., Pharma Manufacturing ...

2022-03-21 14:57:00

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022. Venue: Boston Marriott Copley Place, Boston, M...

Neutral

RBC Capital Markets, LLC, RBC Capital Markets G...

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New Yor...

Neutral

Alliance for Regenerative Medicine, Cell & Gene...

2022-02-26 07:53:00

Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022. Venue: Barcelona, Spain.

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Negative

bluebird bio, Inc. Announces Resignation of Jes...

2022-02-04 12:31:00

bluebird bio, Inc. announced that on January 31, 2022, Jessica Whitten, chief accounting officer and principal accounting officer of the Compa...

Neutral

bluebird bio, Inc. Presents at Advanced Therapi...

2022-01-23 11:43:00

bluebird bio, Inc. Presents at Advanced Therapies Week, Jan-25-2022 through Jan-28-2022. Venue: Miami Beach Convention Centre, Miami, Florida,...

Positive

bluebird bio, Inc. Announces Partial Clinical H...

2021-12-20 13:00:00

bluebird bio, Inc. announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle ce...

Positive

bluebird bio Announces FDA Priority Review of B...

2021-12-17 23:35:00

bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Applicati...

Positive

bluebird bio, Inc. Announces Updated Results fr...

2021-12-12 22:04:00

bluebird bio, Inc. announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin® f...

Positive

New Data At ASH21, Published in Nejm Further De...

2021-12-11 15:33:00

bluebird bio, Inc. presented new results for betibeglogene autotemcel (beti-cel), a deeply studied investigational gene therapy, that demonstr...

Negative

Bluebird Bio, Inc. Announces Resignation of Wen...

2021-11-23 21:47:00

On November 23, 2021, Wendy L. Dixon, Ph.D. notified bluebird bio, Inc.of her resignation as a director from the Company’s Board of Directors,...

Positive

Bluebird Bio, Inc. Announces FDA Priority Revie...

2021-11-22 11:30:00

bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeg...

Positive

bluebird bio, Inc. and Federal Realty to Establ...

2021-11-05 10:58:00

bluebird bio, Inc. announced that it has signed a long-term lease with Federal Realty (Federal) to establish a biotech hub at Assembly Row. Th...

Positive

bluebird bio, Inc. to Present New Gene Therapy ...

2021-11-04 13:00:00

bluebird bio, Inc. announced that new data from its lentiviral vector (LVV) gene addition programs for patients with ß-thalassemia (beta-thal)...

Neutral

bluebird bio, Inc. - Shareholder/Analyst Call

2021-11-04 11:00:00

To host a spotlight and regulatory update on its bb1111 (LentiGlobin® for Sickle Cell Disease) product candidate, an investigational lentivira...

Positive

bluebird bio, Inc. completed the Spin-Off of 2s...

2021-11-04 00:00:00

bluebird bio, Inc. (NasdaqGS:BLUE) agreed to spin-off severe genetic disease and oncology businesses on January 11, 2021. Pursuant to the term...

Positive

National Resilience, Inc. acquired Research Tri...

2021-11-04 00:00:00

National Resilience, Inc. agreed to acquire Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) for $110 million ...

Negative

bluebird Bio, Inc. Announces Board and Committe...

2021-10-05 20:06:00

Effective September 29, 2021, the board of directors of bluebird bio, Inc. appointed Sarah Glickman to the Board as a Class II director and Na...

Neutral

bluebird bio, Inc. Presents at Rare Disease Inn...

2021-10-04 17:31:00

bluebird bio, Inc. Presents at Rare Disease Innovation & Partnering Summit - Virtual, Dec-09-2021 through Dec-10-2021. Presentation Date & Spe...

Neutral

bluebird bio, Inc. Presents at Rare Disease Inn...

2021-10-04 17:22:00

bluebird bio, Inc. Presents at Rare Disease Innovation & Partnering Summit - In-Person, Dec-06-2021 through Dec-07-2021. Venue: Boston, Massac...

Neutral

I.I.R Ltd., Rare Disease Innovation & Partnerin...

2021-10-04 16:47:00

I.I.R Ltd., Rare Disease Innovation & Partnering Summit - In-Person, Dec 06, 2021 through Dec 07, 2021. Venue: Boston, Massachusetts, United States.

Neutral

I.I.R Ltd., Rare Disease Innovation & Partnerin...

2021-10-04 16:47:00

I.I.R Ltd., Rare Disease Innovation & Partnering Summit - Virtual, Dec 09, 2021 through Dec 10, 2021.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Meet...

2021-09-27 23:05:00

bluebird bio, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021. Venue: Carlsbad, California, United States. P...

Positive

bluebird bio, Inc. Submits Biologics License Ap...

2021-09-21 20:15:00

bluebird bio, Inc. announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Admi...

Positive

bluebird bio, Inc. announced that it has receiv...

2021-09-21 00:00:00

On September 21, 2021, bluebird bio, Inc. closed the transaction. The company has received in funding pursuant to Regulation D from two investors.

Neutral

bluebird bio, Inc. Presents at Indegene Digital...

2021-09-16 17:31:00

bluebird bio, Inc. Presents at Indegene Digital Summit, Sep-23-2021 01:00 PM. Speakers: Scott Cleve, VP, Regulatory Operations and Compliance.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Ther...

2021-09-16 14:42:00

bluebird bio, Inc. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Roy Sorek, Director, Quality Assurance.

Neutral

bluebird bio, Inc. Presents at 10th Annual Sick...

2021-09-15 13:42:00

bluebird bio, Inc. Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 02:10 PM. Speakers: Andrew Obenshain, Pres...

Neutral

Indegene, Inc., Indegene Digital Summit, Sep 23...

2021-09-15 12:30:00

Indegene, Inc., Indegene Digital Summit, Sep 23, 2021 through Sep 24, 2021.

Neutral

bluebird bio, Inc. - Special Call

2021-09-13 12:00:00

An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy

Neutral

bluebird bio, Inc. - Special Call

2021-09-13 12:00:00

Focus on bNHL [bbT369] and Solid Tumor Strategy

Neutral

Informa plc, Cell & Gene Therapy Bioprocessing ...

2021-09-08 23:01:00

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.

Neutral

bluebird bio, Inc. Presents at BioProcess Inter...

2021-09-08 22:27:00

bluebird bio, Inc. Presents at BioProcess International Conference & Exhibition, Sep-20-2021 . Speakers: Roy Sorek, Director, Quality Assurance.

Neutral

Informa plc, BioProcess International Conferenc...

2021-09-08 21:27:00

Informa plc, BioProcess International Conference & Exhibition, Sep 20, 2021 through Sep 30, 2021.

Neutral

Global Blood Therapeutics, Inc., Sickle Cell Di...

2021-09-08 21:05:00

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, S...

Neutral

bluebird bio, Inc. Presents at Morgan Stanley 1...

2021-09-07 20:05:00

bluebird bio, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 10:15 AM. Venue: New Windsor, United States.

Neutral

bluebird bio, Inc. Presents at Bank of America ...

2021-09-07 20:05:00

bluebird bio, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 through Sep-17-2021. Presentation Date & Speakers: Se...

Negative

bluebird Bio, Inc. Announces Executive Appointments

2021-09-07 20:05:00

bluebird bio, Inc. announced key management and board appointments in advance of the company’s planned separation, targeted for mid-October, 2...

Negative

Bluebird Bio, Inc. Appoints Gina Consylman as C...

2021-09-07 20:05:00

bluebird bio, Inc. announced the Gina Consylman appointed chief financial officer. Gina Consylman joined bluebird in August 2021 as the CFO of...

Positive

bluebird bio, Inc. announced that it expects to...

2021-09-07 00:00:00

bluebird bio, Inc. announced that it has entered into a securities purchase agreement with the institutional investors for a private placement...

Neutral

bluebird bio, Inc. Presents at PDA Pharmaceutic...

2021-08-27 11:21:00

bluebird bio, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021 . Venue: Washigton, District Of Columbia, United States...

Neutral

Parenteral Drug Association, PDA Pharmaceutical...

2021-08-27 10:55:00

Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021. Venue: Washigton, District Of Colu...

Neutral

Sickle Cell Advocacy, 8th Annual Sickle Cell Wa...

2021-08-20 12:44:00

Sickle Cell Advocacy, 8th Annual Sickle Cell Warriors Convention, Aug 25, 2021 through Aug 29, 2021.

Neutral

bluebird bio, Inc. Presents at Supply Chain & L...

2021-08-14 17:42:00

bluebird bio, Inc. Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-28-2021 09:00 AM. Speakers: Beth Gardner, Senior Direct...

Neutral

Hanson Wade Limited, Supply Chain & Logistics f...

2021-08-14 15:18:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021.

Neutral

bluebird bio, Inc. to Report Q2, 2021 Results o...

2021-08-05 20:05:00

bluebird bio, Inc. announced that they will report Q2, 2021 results on Aug 09, 2021

Neutral

bluebird bio, Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-08-05 20:05:00

bluebird bio, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

bluebird bio, Inc. Presents at 12th Annual Wedb...

2021-08-05 17:05:00

bluebird bio, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 12:00 PM.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Ther...

2021-08-05 05:40:00

bluebird bio, Inc. Presents at Cell & Gene Therapy USA, Sep-28-2021 through Sep-29-2021. Presentation Date & Speakers: Sep-28-2021, Neary Detr...

Neutral

Reuters Events, Cell & Gene Therapy USA, Sep 28...

2021-08-05 03:58:00

Reuters Events, Cell & Gene Therapy USA, Sep 28, 2021 through Sep 29, 2021.

Positive

Bluebird Bio and National Resilience Announce S...

2021-07-28 12:04:00

National Resilience, Inc. (Resilience) and bluebird bio, Inc. announced a strategic alliance aimed to accelerate the early research, developme...

Positive

National Resilience, Inc. agreed to acquire Res...

2021-07-28 00:00:00

National Resilience, Inc. agreed to acquire Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) for $110 million ...

Positive

bluebird bio Receives EC Approval for SKYSONA

2021-07-21 09:00:00

bluebird bio, Inc. announced that the European Commission (EC) has granted marketing authorization of SKYSONA™(elivaldogene autotemcel, Lenti-...

Positive

bluebird bio, Inc. Announces Positive Recommend...

2021-07-09 11:30:00

bluebird bio, Inc. announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based...

Neutral

bluebird bio, Inc. Presents at MRNA-Based Thera...

2021-07-06 14:18:00

bluebird bio, Inc. Presents at MRNA-Based Therapeutics Summit, Jul-13-2021 03:00 PM. Speakers: Jimmy Chu, Scientist II, mRNA Process Development.

Neutral

Hanson Wade Limited, MRNA-Based Therapeutics Su...

2021-07-06 13:00:00

Hanson Wade Limited, MRNA-Based Therapeutics Summit, Jul 13, 2021.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell Microcap Value Index

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell Microcap Value Index

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 3000E Index

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 3000E Index

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 3000E Value Index

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 3000E Value Index

Positive

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell Microcap Index

2022-06-24 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell Microcap Index

Negative

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

2022-06-22 00:00:00

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Negative

bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P Biotechnology Select Industry Index

2022-06-11 00:00:00

bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P Biotechnology Select Industry Index

Positive

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

2022-06-10 10:03:00

On June 9, 2022, bluebird bio, Inc. ('bluebird' or the 'Company') announced that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) has recommended approval of elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy in patients less than 18 years of age who do not have an available and willing human leukocyte antigen-matched sibling hematopoietic stem cell donor.

Positive

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

2022-06-09 22:14:00

bluebird bio, Inc. announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age who do not have an available and willing human leukocyte antigen (HLA)-matched sibling hematopoietic stem cell (HSC) donor. CALD is a rare, progressive, neurodegenerative disease that primarily affects young boys and causes behavioral, cognitive, and neurological deficits. Nearly half of patients who do not receive treatment die within five years of symptom onset. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is currently the only effective treatment option but is associated with serious potential complications and mortality that increase in patients without a matched sibling donor. If approved, eli-cel will be the first approved gene therapy to address the underlying genetic cause of disease for patients living with CALD in the U.S. – offering the more than 70% of patients diagnosed with CALD who do not have a matched sibling donor an alternative to allo-HSCT. The eli-cel clinical program was placed on a clinical hold following a Suspected Unexpected Serious Adverse Reaction (SUSAR) of myelodysplastic syndrome (MDS) in August 2021. Consistent with this known risk, two additional cases of MDS have subsequently been reported. All patients who received eli-cel in the clinical program continue to be closely monitored, per study protocols.

Neutral

bluebird bio, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 08:00 AM

2022-05-10 10:23:00

bluebird bio, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 08:00 AM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

bluebird bio, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 04:00 PM

2022-05-10 10:23:00

bluebird bio, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 04:00 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

2022-05-02 21:38:00

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022, at 08:30 Eastern Daylight. Location: 455 Grand Union Boulevard Somerville Massachusetts United States Agenda: To elect Nick Leschly and Najoh Tita-Reid as Class III members of the Board of Directors, to serve until the Company’s 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified; to approve, on a non-binding, advisory basis, the compensation paid to the Company’s named executive officers; to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact any other business that may properly come before the meeting or any adjournment thereof.

Negative

bluebird bio, Inc. Appoints Jason F. Cole as Principal Accounting Officer

2022-05-02 20:06:00

On April 27, 2022, the board of the directors of bluebird bio, Inc. appointed Jason F. Cole, as the Company's principal accounting officer in addition to his current role as the Company's Chief Strategy and Financial Officer and Treasurer and its principal financial officer, effective immediately. Prior to these roles, Jason F. Cole, served as the Company's Chief Business Officer since November 2021. Mr. Cole previously served as the Company’s Chief Operating and Legal Officer from February 2019 to November 2021.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022

2022-04-17 03:23:00

bluebird bio, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022 . Venue: Barcelona, Spain.

Neutral

Hanson Wade Limited, Gene Therapy Analytical Development Europe, May 30, 2022 through Jun 01, 2022

2022-04-06 17:15:00

Hanson Wade Limited, Gene Therapy Analytical Development Europe, May 30, 2022 through Jun 01, 2022. Venue: London, United Kingdom.

Neutral

bluebird bio, Inc. Presents at Gene Therapy Analytical Development Europe, Jun-01-2022 02:00 PM

2022-04-06 17:15:00

bluebird bio, Inc. Presents at Gene Therapy Analytical Development Europe, Jun-01-2022 02:00 PM. Venue: London, United Kingdom. Speakers: Ilya Shestopalov, Director and Analytical, Product Lead.

Neutral

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022. Venue: Boston, Massachusetts, United States.

Neutral

bluebird bio, Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022

2022-04-06 17:15:00

bluebird bio, Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022 . Venue: Boston, Massachusetts, United States. Speakers: Tom Croce, VP, Patient Advocacy.

Neutral

bluebird bio, Inc. - Shareholder/Analyst Call

2022-04-05 11:00:00

bluebird bio, Inc. - Shareholder/Analyst Call

Neutral

bluebird bio, Inc. Presents at Pharma Manufacturing World Summit, Mar-29-2022

2022-03-29 08:36:00

bluebird bio, Inc. Presents at Pharma Manufacturing World Summit, Mar-29-2022 . Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Derek Adams, Chief Technology and Manufacturing Officer.

Neutral

bluebird bio, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 03:20 PM

2022-03-22 05:03:00

bluebird bio, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 03:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Andrew Obenshain, President, CEO & Director.

Neutral

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022

2022-03-21 14:57:00

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022. Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States.

Neutral

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022

2022-02-26 07:53:00

Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022. Venue: Barcelona, Spain.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Negative

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

2022-02-04 12:31:00

bluebird bio, Inc. announced that on January 31, 2022, Jessica Whitten, chief accounting officer and principal accounting officer of the Company provided notice of her resignation from bluebird effective upon the Company’s filing of its annual report on Form 10-K covering the period ended December 31, 2021. Gina Consylman, bluebird’s chief financial officer and principal financial officer will serve as interim principal accounting officer until Ms. Whitten’s replacement is hired.

Neutral

bluebird bio, Inc. Presents at Advanced Therapies Week, Jan-25-2022 through Jan-28-2022

2022-01-23 11:43:00

bluebird bio, Inc. Presents at Advanced Therapies Week, Jan-25-2022 through Jan-28-2022. Venue: Miami Beach Convention Centre, Miami, Florida, United States. Presentation Date & Speakers: Jan-28-2022, Clark Paramore, HEAD of VALUE DEMONSTRATION, VICE PRESIDENT of HEOR, Clark Paramore, Head of Value Determination, Vice President of HEOR.

Positive

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

2021-12-20 13:00:00

bluebird bio, Inc. announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD) on partial clinical hold for patients under the age of 18. The partial, temporary suspension relates to an ongoing investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment. This patient is clinically well and there is no evidence of malignancy or clonal predominance. Enrollment and dosing for patients 18 and older living with SCD in the HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies are continuing as planned. Consistent with the FDA’s clinical hold procedures, bluebird anticipates receiving written questions from the agency in early 2022 and will work quickly to respond in order to resolve the partial hold. The company is evaluating what impact, if any, the partial clinical hold may have on first quarter 2023 projected timing for the lovo-cel biologics license application (BLA) submission. As previously communicated, bluebird has treated all patients in HGB-206 Group C who will form the primary basis of efficacy for approval, with the demonstration of analytical comparability and validation of commercial manufacturing process as the key remaining actions prior to submission of the planned BLA. About lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin® for SCD, bb1111): lovotibeglogene autotemcel (lovo-cel) gene therapy is an investigational one-time treatment being studied for sickle cell disease (SCD), that is designed to add functional copies of a modified form of the ß-globin gene (ßA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once patients have the ßA-T87Q-globin gene, their red blood cells (RBCs) can produce anti-sickling hemoglobin (HbAT87Q) that decreases the proportion of HbS, with the goal of reducing sickled RBCs, hemolysis, and other complications. bluebird bio’s clinical development program for lovo-cel includes the completed Phase 1/2 HGB-205 and ongoing Phase 1/2 HGB-206 and Phase 3 HGB-210 studies. bluebird bio is also conducting a long-term safety and efficacy follow-up study (LTF-307) for people who have participated in bluebird bio sponsored clinical studies of lovo-cel. The safety profile of the lovo-cel treatment regimen is predominately reflective of the known risks of autologous stem cell transplantation and myeloablative single-agent busulfan conditioning, as well as underlying SCD. Adverse drug reactions due to lovo-cel include hot flush, decreased blood pressure, acute myeloid leukemia (AML), and anemia. As of February 17, 2021, a total of 49 patients have been treated with lovo-cel, with up to six years of patient follow-up, in the HGB-205 (n=3), HGB-206 (n=44), and HGB-210 (n=2) clinical studies. The HGB-206 total includes: Group A (n=7), B (n=2), and C (n=35), representing progressive adaptations to the manufacturing and treatment processes. In the Group C cohort of the Phase 1/2 HGB-206 study, no severe vaso-occlusive events (VOEs) were reported with up to 24 months of follow-up in patients with a history of at least four severe VOEs and at least six months of follow-up. In the initial cohort (Group A) of the HGB-206 study,two patients treated with lovo-cel developed AML. After thorough investigations into the cases, bluebird bio determined that these were unlikely related to the insertion of bluebird’s lentiviral vector (LVV) gene therapy for SCD.

Positive

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

2021-12-17 23:35:00

bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for elivaldogene autotemcel (eli-cel, Lenti-D®), the company’s gene therapy for cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age. Eli-cel is an investigational one-time gene therapy, custom-designed to treat the underlying cause of this irreversible neurodegenerative disease and to stabilize neurologic function. The agency set a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2022. If approved, eli-cel will be the first approved treatment to address the underlying genetic cause of disease for patients living with CALD in the U.S. – offering appropriate patients an alternative to allogeneic hematopoietic stem cell transplant (allo-HSCT), which is associated with serious potential complications and mortality that increase in patients without a matched sibling donor. It is estimated that more than 70% of patients diagnosed with CALD do not have a matched sibling donor.

Positive

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

2021-12-12 22:04:00

bluebird bio, Inc. announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin® for SCD, bb1111) gene therapy for sickle cell disease, including further analyses from its pivotal cohort, HGB-206 Group C, following enhancements to the manufacturing protocols and treatment process. In addition to continued complete resolution of severe vaso-occlusive events (VOEs), patients in Group C achieved near normal levels of key hemolysis markers and experienced sustained improvements in patient-reported quality of life following treatment. Data were presented in two oral sessions at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021, at the Georgia World Congress Center in Atlanta and virtually; select data from the Group C cohort of the HGB-206 study were simultaneously published in The New England Journal of Medicine (NEJM). Clinical studies evaluating lovo-cel in sickle cell disease represent the largest sickle cell disease gene therapy data set to date. As of February 17, 2021, 49patients have been treated with lovo-celwith up to six years of patient follow-up (median: 24 months) across the HGB-205 (n=3), HGB-206 (n=44) and HGB-210 (n=2) clinical studies, representing more than 109 total patient-years of data. The Phase 1/2 HGB-206 trial includes Groups A (n=7), B (n=2) and C (n=35), reflecting progressive adaptations to the treatment and manufacturing processes. Sickle cell disease is a serious, progressive and debilitating genetic disease caused by a single mutation in the ß-globin gene that leads to the production of abnormal sickle hemoglobin (HbS). HbS causes red blood cells (RBCs) to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and unpredictable, painful VOEs requiring frequent hospitalization. In the U.S., the median age of death for someone with sickle cell disease is 43-46 years. Additionally, one in four people living with sickle cell disease experience a stroke by age 45. In the HGB-206 study, VOEs are defined as episodes of acute pain with no medically determined cause other than a vaso-occlusion, lasting more than two hours and severe enough to require care at a medical facility. This includes acute episodes of pain, acute chest syndrome (ACS), acute hepatic sequestration and acute splenic sequestration. A severe VOE requires a 24-hour hospital stay or emergency room visit or at least two visits to a hospital or emergency room over a 72-hour period, with both visits requiring intravenous treatment. lovo-cel adds functional copies of a modified form of the ß-globin gene (ßA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once patients have the ßA-T87Q-globin gene, their RBCs can produce anti-sickling hemoglobin (HbAT87Q) that decreases the proportion of HbS, thereby reducing sickled RBCs, hemolysis and other complications.

Positive

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

2021-12-11 15:33:00

bluebird bio, Inc. presented new results for betibeglogene autotemcel (beti-cel), a deeply studied investigational gene therapy, that demonstrate adult and pediatric patients living with ß-thalassemia (beta-thal) who require regular red blood cell (RBC) transfusions can produce normal or near-normal levels of total hemoglobin and continue to remain transfusion-free, and achieve stable iron markers, through up to seven years of follow-up (n=3). These findings further support beti-cel as a potentially curative one-time treatment option that addresses the underlying genetic cause of beta-thal and mitigates the burdens associated with the practical management of the disease Transfusion-dependent beta-thal is a severe genetic disease caused by mutations in the ß-globin gene, which may cause significantly reduced or absent adult hemoglobin (Hb) production. This can result in severe anemia and lifelong dependence on RBC transfusions, a lengthy process that patients typically undergo every 3-4 weeks. Despite advances in treatment and improved transfusion techniques, transfusions only temporarily address symptoms of anemia and people with beta-thal who require regular transfusions have an increased risk for morbidity and mortality due to treatment- and disease-related iron overload and its complications. beti-cel is a one-time gene therapy that adds functional copies of a modified form of the ß-globin gene (ßA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once patients have the ßA-T87Q-globin gene, the HSCs have the potential to produce gene therapy-derived adult Hb (HbAT87Q) at levels that can eliminate the need for transfusions. In studies of beti-cel, transfusion independence is defined as no longer needing RBC transfusions for at least 12 months while maintaining a weighted average Hb of at least 9 g/dL. As of the data cut-off of August 18, 2021, a total of 63 pediatric, adolescent and adult patients, including 20 patients with at least five years of follow-up, 11 with at least six years and three with up to seven years across ß0/ß0 and non-ß0/ß0 genotypes, have been treated with beti-cel in the Phase 1/2 HGB-204 (Northstar) and HGB-205 studies and the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies. Data from bluebird bio’s Phase 1/2 and Phase 3 clinical studies represent more than 240 patient-years of experience with beti-cel and the longest available follow-up data in beta-thal patients requiring regular RBC transfusions treated with one-time gene therapy. Adverse reactions considered related to beti-cel were few and consisted primarily of non-serious infusion-related reactions that occurred on the day of infusion (e.g., abdominal pain, hot flush, dyspnea, tachycardia and non-cardiac chest pain) and cytopenias (e.g. thrombocytopenia, leukopenia and neutropenia). Pain in extremity shortly after treatment was also documented. One of these adverse events (AE) was a serious adverse event (SAE) of thrombocytopenia considered possibly related to beti-cel and has resolved. The majority of AEs and SAEs in the beti-cel clinical development program were unrelated to beti-cel and consistent with the known side effects of HSC collection and busulfan conditioning regimen (including several SAEs of veno-occlusive disease that resolved with treatment). Updated Long-Term Efficacy & Safety Results (Long-term follow-up study, LTF-303) After participating in and completing the two years of follow-up in any of the Phase 1/2 (HGB-204, HGB-205) or Phase 3 studies (HGB-207, HGB-212), patients treated with beti-cel were invited to enroll in a 13-year long-term follow-up study, LTF-303. As of August 18, 2021, 57 of 63 beti-cel-treated patients across age groups and genotypes spanning a broad range of the most severe ß0/ß0 and non-ß0/ß0 genotypes were enrolled in LTF-303 (22 treated in Phase 1/2 studies, 35 treated in Phase 3 studies) with a median post-infusion follow-up of 41.5 months (min-max: 23-87.5). Twenty patients enrolled in LTF-303 have at least five years of follow-up. Transfusion Independence (TI) Of the 57 patients enrolled in LTF-303, 46 patients achieved TI: 15/22 (68%) patients treated in Phase 1/2 and 31/35 (89%) patients treated in Phase 3. All 46 patients who achieved TI maintained it through last follow-up in LTF-303, demonstrating the long-term durability of beti-cel. Phase 1/2 patients had a median duration of ongoing TI of 65.9 months (min-max: 19.8-84.5) and Phase 3 patients had a median ongoing TI duration of 32 months (min-max: 18.2-49.1). Weighted average Hb in patients who achieved TI reached normal or near-normal levels in the Phase 1/2 studies (10.3 g/dL; min-max: 9.1-13.2) and in the Phase 3 studies (11.6 g/dL; min-max: 9.5-13.7). Iron Marker StabilizationPatients who require regular blood transfusions need to reduce excess iron caused by chronic blood transfusions. For people living with beta-thal, iron can be removed from the body in several ways, including chelation (pharmacological removal). Prior to beti-cel infusion, all patients were on iron chelation. Importantly, the majority of patients who achieved TI (n=46/57) that restarted iron chelation after infusion have since stopped (59%, 20/34); and 24% of those who achieved TI (11/46) were able to receive phlebotomy (blood removal), which is another method for iron reduction that is only possible for patients who have sufficient hemoglobin levels without RBC transfusions. This supports the potential for beti-cel to reduce the treatment burden associated with iron management. A sub-analysis of iron status in LTF-303 included 16 patients who achieved TI and stopped chelation, with at least nine months of follow-up after discontinuation of chelation. The sub-analysis showed iron reduction in response to chelation and stabilization of iron markers after chelation was discontinued. LTF-303 SafetyThere were no deaths, no vector-derived replication-competent lentivirus, and no events of insertional oncogenesis or malignancy in LTF-303. No drug-related AEs were reported. Serious AEs unrelated to beti-cel included infertility issues (gonadotropic insufficiency, ectopic pregnancy, fetal death as a result of a miscarriage), gallbladder disease (gall bladder wall thickening/polyp), cholelithiasis, infection and low white blood cell count in the setting of a wild-type HIV (bacteremia, neutropenia), and individual events of diabetic ketoacidosis, pulmonary embolism, and major depression. Pulmonary embolism occurred concurrently with diabetic ketoacidosis in a patient with a history of thromboembolic events. Each event was reported once.

Negative

Bluebird Bio, Inc. Announces Resignation of Wendy L. Dixon as Director, and Its Audit Committee and Compensation Committee

2021-11-23 21:47:00

On November 23, 2021, Wendy L. Dixon, Ph.D. notified bluebird bio, Inc.of her resignation as a director from the Company’s Board of Directors, and its Audit Committee and Compensation Committee, effective immediately. Dr. Dixon’s resignation was not caused by any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Positive

Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

2021-11-22 11:30:00

bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with ß-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatment that addresses the underlying genetic cause of disease for patients living with ß-thalassemia in the U.S.—offering an alternative to regular RBC transfusions and iron chelation therapy. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 20, 2022. The BLA for beti-cel is based on data from bluebird bio’s Phase 3 studies HGB-207 (Northstar-2) and HGB-212 (Northstar-3), the Phase 1/2 HGB-204 (Northstar) and HGB-205 studies, and the long-term follow-up study LTF-303. Together, these studies represent more than 220 patient-years of experience with beti-cel. As of March 9, 2021, the results include a total of 63 pediatric, adolescent and adult patients, including long-term efficacy and safety results in two patients with more than seven years follow-up.

Positive

bluebird bio, Inc. and Federal Realty to Establish Biotech Footprint at Assembly Row

2021-11-05 10:58:00

bluebird bio, Inc. announced that it has signed a long-term lease with Federal Realty (Federal) to establish a biotech hub at Assembly Row. The 61,000 square foot facility to be located at 455 Grand Union Blvd. in Somerville is designed to meet the changing needs of bluebird bio’s business, including its dedicated focus on gene therapies for severe genetic diseases following the recent spinoff of its oncology portfolio. The company expects to move approximately 425 employees to its new headquarters in spring of 2022. The workspace is designed to enable a distributed work model and to allow for increased engagement and productivity for all employees, as hybrid work is here to stay. bluebird estimates the move to Assembly Row will result in more than $120 million in cumulative cost savings over the next six years. The company will maintain laboratory space and operations at 60 Binney St. in Cambridge through 2023. The new facility in Somerville offers easy access to the MBTA Orange Line (Assembly stop) and offers multiple amenities, including a state-of-the-art fitness center, an on-location kids’ room and ample bike storage, in addition to Assembly Row’s large array of dining, shopping, entertainment and health and wellness benefits. The building was designed in accordance with LEED Gold Core & Shell and is currently pursuing certification.

Positive

bluebird bio, Inc. to Present New Gene Therapy Data at the 63rd American Society of Hematology Annual Meeting and Exposition

2021-11-04 13:00:00

bluebird bio, Inc. announced that new data from its lentiviral vector (LVV) gene addition programs for patients with ß-thalassemia (beta-thal) who require regular red blood cell (RBC) transfusions and sickle cell disease will be presented at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021, at the Georgia World Congress Center in Atlanta, Georgia, and virtually. bluebird bio will present updated efficacy and safety results from its clinical programs, including long-term follow-up results of betibeglogene autotemcel (beti-cel) that demonstrate iron level stabilization in adult and pediatric patients living with beta-thal who require regular RBC transfusions followed for up to seven years; the oral presentation will also be featured in the ASH press program. Additional beti-cel data include improvement in health-related quality of life among adult and pediatric patients in the HGB-207 and HGB-212 Phase 3 studies. Updated results from the Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease gene therapy (bb1111) will also be presented, including new analyses demonstrating improvements in clinical and biologic outcomes, as well as updated and longer-term data from HGB-206 Group C that show sustained improvements in quality of life. betibeglogene autotemcel (beti-cel) (pronounced beh TEE cell) is a one-time gene therapy custom-designed to treat the underlying cause of beta-thalassemia in patients who require regular transfusions. In order to correct the deficiency of adult hemoglobin that is the hallmark of beta-thalassemia, beti-cel adds functional copies of a modified form of the ß-globin gene (ßA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once a patient has the ßA-T87Q-globin gene, they have the potential to produce HbAT87Q, which is beti-cel-derived adult hemoglobin (Hb) at levels that may eliminate or significantly reduce the need for transfusions. In beti-cel studies, transfusion independence (TI) is defined as no longer needing RBC transfusions for at least 12 months while maintaining a weighted average Hb of at least 9 g/dL. Across Phase 3 studies, 89% (32/36) of evaluable patients across ages and genotypes, including pediatric patients as young as four years of age and those with the most severe ß0/ß0 genotypes, achieved TI. beti-cel is manufactured using the BB305 lentiviral vector (LVV), a third-generation, self-inactivating LVV that has been studied for more than a decade. Adverse reactions considered related to beti-cel were uncommon and consisted primarily of infusion-related reactions (abdominal pain, hot flush, dyspnea, tachycardia and non-cardiac chest pain) and cytopenias (thrombocytopenia, leukopenia and neutropenia). Pain in extremity shortly after treatment was also documented. One of these adverse events (AE) was a serious adverse event (SAE) of thrombocytopenia considered possibly related to beti-cel. The majority of AEs and SAEs unrelated to beti-cel were consistent with the known side effects of HSC collection and bone marrow ablation with busulfan (including several SAEs of veno-occlusive disease). The Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies evaluating beti-cel are ongoing; enrollment is complete, and all patients have been treated. bluebird bio is also conducting a long-term follow-up study, LTF-303, to monitor safety and efficacy for people who have participated in bluebird bio-sponsored beti-cel clinical studies through 15 years, post treatment with beti-cel. A biologics license application (BLA) for beti-cel has been submitted to the FDA. LentiGlobin gene therapy for sickle cell disease (bb1111) is an investigational one-time treatment being studied for sickle cell disease, that is designed to add functional copies of a modified form of the ß-globin gene (ßA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once patients have the ßA-T87Q-globin gene, their red blood cells can produce anti-sickling hemoglobin (HbAT87Q) that decreases the proportion of HbS, with the goal of reducing sickled red blood cells, hemolysis and other complications. bluebird bio’s clinical development program for LentiGlobin for sickle cell disease includes the completed Phase 1/2 HGB-205 and ongoing Phase 1/2 HGB-206 and Phase 3 HGB-210 studies. bluebird bio is also conducting a long-term safety and efficacy follow-up study (LTF-307) for people who have participated in bluebird bio sponsored clinical studies of LentiGlobin for sickle cell disease. The safety data profile remains generally consistent with the risks of autologous stem cell transplantation and myeloablative single-agent busulfan conditioning, as well as underlying SCD. In the Group C cohort of the HGB-206 study, one patient with underlying cardiopulmonary disease and SCD-related complications died 20 months post-treatment; the treating physician and an independent monitoring committee agreed his death was unlikely related to LentiGlobin for SCD. In the initial cohort (Group A) of the HGB-206 study,two patients treated with LentiGlobin for SCD developed acute myeloid leukemia (AML). After thorough investigations into the cases, bluebird bio determined that these were unlikely related to the insertion of bluebird’s lentiviral vector (LVV) gene therapy for SCD.

Neutral

bluebird bio, Inc. - Shareholder/Analyst Call

2021-11-04 11:00:00

To host a spotlight and regulatory update on its bb1111 (LentiGlobin® for Sickle Cell Disease) product candidate, an investigational lentiviral vector gene therapy for sickle cell disease

Positive

bluebird bio, Inc. completed the Spin-Off of 2seventy bio, Inc. (NasdaqGS:TSVT.V).

2021-11-04 00:00:00

bluebird bio, Inc. (NasdaqGS:BLUE) agreed to spin-off severe genetic disease and oncology businesses on January 11, 2021. Pursuant to the terms of the spin-off, bluebird bio, Inc., will separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies. bluebird bio, Inc., will retain focus on severe genetic disease (SGD) and will launch its oncology business (“Oncology Newco”) as a new entity. It is anticipated that the spin out of Oncology Newco is to be tax-free to shareholders. Upon separation, bluebird bio plans to distribute 100% of the outstanding shares of 2seventy bio common stock to bluebird’s shareholders in a 3:1 ratio. For every three shares of bluebird bio stock, current shareholders will receive one share of 2seventy bio stock. bluebird bio, Inc., plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. As of October 8, 2021, Najoh Tita-Reid has been appointed to the bluebird bio, Inc., board of directors. Sarah Glickman has balso been appointed to the bluebird bio, Inc., board of directors and is expected to join the 2seventy bio board of directors as Audit Committee Chair upon separation. The transaction is subject to receipt of a favorable Internal Revenue Service (IRS) ruling. bluebird bio, Inc.’s Board of Directors approved the intent to separate into two companies. Closing of the separation anticipated to be in the Q4 2021. As of October 8, 2021, the transaction is expected to complete in early November 2021. Goldman Sachs & Co. LLC is serving as exclusive financial adviser to bluebird bio and Goodwin Procter LLP is serving as its legal counsel. bluebird bio, Inc. completed the Spin-Off of 2seventy bio, Inc. (NasdaqGS:TSVT.V) on November 4, 2021. 2seventy will begin regular-way trading on the NASDAQ under the stock ticker symbol “TSVT” on November 5, 2021. bluebird bio will continue to trade under the stock ticker symbol “BLUE.”

Positive

National Resilience, Inc. acquired Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) for $110 million.

2021-11-04 00:00:00

National Resilience, Inc. agreed to acquire Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) for $110 million on July 28, 2021. Resilience will retain all of the more than 100 highly skilled technical staff and administrators currently employed at the site. In a related transaction, National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies. Resilience will continue to support vector supply for both bluebird bio and 2seventy bio, bluebird’s spin-off oncology cell therapy company that is expected to launch by the end of 2021. The two companies are also finalizing a definitive agreement to establish partner programs that will share expense and revenue for successful commercialized oncology products and in parallel establish a next-generation manufacturing R&D collaboration. Resilience will continue to invest in the advancement of new technologies and expand the workforce as part of the company’s mission to build a digitally connected, end-to-end biomanufacturing ecosystem. Upon completion of the acquisition, the Resilience network will include 10 sites in North America with more than 1 million square feet of manufacturing, development, and support space. The closing of the transaction will be subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the negotiation of certain definitive agreements and other customary closing conditions. National Resilience, Inc. completed the acquisition of Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) on November 4, 2021.

Negative

bluebird Bio, Inc. Announces Board and Committee Appointments

2021-10-05 20:06:00

Effective September 29, 2021, the board of directors of bluebird bio, Inc. appointed Sarah Glickman to the Board as a Class II director and Najoh Tita-Reid to the Board as a Class III director, and increased the size of the board to eleven. Ms. Tita-Reid has been appointed as a member of the Nominating and Corporate Governance Committee and the Compensation Committee of the Board, effective upon the consummation of the planned separation of the Company's oncology programs and portfolio from its severe genetic disease programs and portfolio through the spinoff of 2seventy bio, Inc. as an independent, publicly-traded Delaware corporation (the Separation). Glickman has not been appointed to any committees of the Board. Since September 2020, Sarah Glickman has served as the Chief Financial Officer for Criteo. Since April 2021, Najoh Tita-Reid has served as Global Chief Marketing Officer for Logitech.

Neutral

bluebird bio, Inc. Presents at Rare Disease Innovation & Partnering Summit - Virtual, Dec-09-2021 through Dec-10-2021

2021-10-04 17:31:00

bluebird bio, Inc. Presents at Rare Disease Innovation & Partnering Summit - Virtual, Dec-09-2021 through Dec-10-2021. Presentation Date & Speakers: Dec-09-2021, Tom Croce, Vice President, Patient Advocacy. Dec-10-2021, Tom Croce, Vice President, Patient Advocacy.

Neutral

bluebird bio, Inc. Presents at Rare Disease Innovation & Partnering Summit - In-Person, Dec-06-2021 through Dec-07-2021

2021-10-04 17:22:00

bluebird bio, Inc. Presents at Rare Disease Innovation & Partnering Summit - In-Person, Dec-06-2021 through Dec-07-2021. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: Dec-06-2021, Tom Croce, Vice President, Patient Advocacy, Tom Croce, VP, Patient Advocacy. Dec-07-2021, Tom Croce, Vice President, Patient Advocacy.

Neutral

I.I.R Ltd., Rare Disease Innovation & Partnering Summit - In-Person, Dec 06, 2021 through Dec 07, 2021

2021-10-04 16:47:00

I.I.R Ltd., Rare Disease Innovation & Partnering Summit - In-Person, Dec 06, 2021 through Dec 07, 2021. Venue: Boston, Massachusetts, United States.

Neutral

I.I.R Ltd., Rare Disease Innovation & Partnering Summit - Virtual, Dec 09, 2021 through Dec 10, 2021

2021-10-04 16:47:00

I.I.R Ltd., Rare Disease Innovation & Partnering Summit - Virtual, Dec 09, 2021 through Dec 10, 2021.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021

2021-09-27 23:05:00

bluebird bio, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021. Venue: Carlsbad, California, United States. Presentation Date & Speakers: Oct-12-2021, Thomas J. Klima, Chief Commercial Officer of Severe Genetic Disease. Oct-13-2021, Kristin Wolff, Vice President, Global Policy Strategy and U.S. Government Payer.

Positive

bluebird bio, Inc. Submits Biologics License Application to FDA for Betibeglogene Autotemcel (beti-cel) Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

2021-09-21 20:15:00

bluebird bio, Inc. announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with ß-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation for the treatment of transfusion-dependent ß-thalassemia (TDT). If approved, beti-cel will be the first hematopoietic (blood) stem cell (HSC) ex-vivo gene therapy for patients in the United States. The BLA submission for beti-cel is based on data from patients treated in bluebird bio studies, including the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies, and the Phase 1/2 HGB-204 (Northstar) and HGB-205 studies. Together, these studies represent more than 220 patient-years of experience with beti-cel. As of March 9, 2021, the results include a total of 63 pediatric, adolescent and adult patients who have been treated with beti-cel across ß0/ß0 and non-ß0/ß0 genotypes. The data include two patients with up to seven years of follow-up, eight with at least six years of follow-up and 19 with at least five years of follow-up, and were most recently shared during the 26th Annual Congress of the European Hematology Association (EHA2021 Virtual).

Positive

bluebird bio, Inc. announced that it has received $74.977264 million in funding from Baker Bros. Advisors LP

2021-09-21 00:00:00

On September 21, 2021, bluebird bio, Inc. closed the transaction. The company has received in funding pursuant to Regulation D from two investors.

Neutral

bluebird bio, Inc. Presents at Indegene Digital Summit, Sep-23-2021 01:00 PM

2021-09-16 17:31:00

bluebird bio, Inc. Presents at Indegene Digital Summit, Sep-23-2021 01:00 PM. Speakers: Scott Cleve, VP, Regulatory Operations and Compliance.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021

2021-09-16 14:42:00

bluebird bio, Inc. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Roy Sorek, Director, Quality Assurance.

Neutral

bluebird bio, Inc. Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 02:10 PM

2021-09-15 13:42:00

bluebird bio, Inc. Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 02:10 PM. Speakers: Andrew Obenshain, President of Severe Genetic Diseases.

Neutral

Indegene, Inc., Indegene Digital Summit, Sep 23, 2021 through Sep 24, 2021

2021-09-15 12:30:00

Indegene, Inc., Indegene Digital Summit, Sep 23, 2021 through Sep 24, 2021.

Neutral

bluebird bio, Inc. - Special Call

2021-09-13 12:00:00

An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy

Neutral

bluebird bio, Inc. - Special Call

2021-09-13 12:00:00

Focus on bNHL [bbT369] and Solid Tumor Strategy

Neutral

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021

2021-09-08 23:01:00

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.

Neutral

bluebird bio, Inc. Presents at BioProcess International Conference & Exhibition, Sep-20-2021

2021-09-08 22:27:00

bluebird bio, Inc. Presents at BioProcess International Conference & Exhibition, Sep-20-2021 . Speakers: Roy Sorek, Director, Quality Assurance.

Neutral

Informa plc, BioProcess International Conference & Exhibition, Sep 20, 2021 through Sep 30, 2021

2021-09-08 21:27:00

Informa plc, BioProcess International Conference & Exhibition, Sep 20, 2021 through Sep 30, 2021.

Neutral

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, Sep 15, 2021

2021-09-08 21:05:00

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, Sep 15, 2021.

Neutral

bluebird bio, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 10:15 AM

2021-09-07 20:05:00

bluebird bio, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 10:15 AM. Venue: New Windsor, United States.

Neutral

bluebird bio, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 through Sep-17-2021

2021-09-07 20:05:00

bluebird bio, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 through Sep-17-2021. Presentation Date & Speakers: Sep-16-2021, Andrew Obenshain, CEO, Richard Colvin, Chief Medical Officer, Tom Klima, CCO. Sep-17-2021, Nick Leschly, President, CEO & Director, Nicola Heffron, Chief Operating Officer of Oncology, Philip D. Gregory, Chief Scientific Officer, William D. Baird, CFO and Principal Financial & Accounting Officer.

Negative

bluebird Bio, Inc. Announces Executive Appointments

2021-09-07 20:05:00

bluebird bio, Inc. announced key management and board appointments in advance of the company’s planned separation, targeted for mid-October, 2021. The company also outlined plans for investor events and participation in investor conferences leading up to the separation. The board welcome Marcela Maus to bluebird bio’s board of directors. Marcela Maus, M.D., Ph.D., is currently an associate professor at Harvard Medical School, the Paula O’Keefe chair in oncology and director of cellular immunotherapy at Mass General Cancer Center, as well as an attending physician in the Hematopoietic Cell Transplant and Cell Therapy division of Oncology at Mass General Cancer Center.

Negative

Bluebird Bio, Inc. Appoints Gina Consylman as Chief Financial Officer

2021-09-07 20:05:00

bluebird bio, Inc. announced the Gina Consylman appointed chief financial officer. Gina Consylman joined bluebird in August 2021 as the CFO of the severe genetic disease business, overseeing finance, tax, accounting, treasury, insurance and investor relations. She has over 25 years of experience in finance, investor relations, strategy and business development. Prior to joining bluebird, she served as senior vice president and CFO at Ironwood Pharmaceuticals. Before Ironwood, Gina served as vice president, corporate controller and principal accounting officer at Analogic Corporation, a publicly-held healthcare and security technology solutions company, where she oversaw the company’s global accounting and treasury teams.

Positive

bluebird bio, Inc. announced that it expects to receive $74.977264 million in funding from Baker Bros. Advisors LP

2021-09-07 00:00:00

bluebird bio, Inc. announced that it has entered into a securities purchase agreement with the institutional investors for a private placement of 2,272,727 common shares, par value $0.01 per share, at an issue price of $16.50 per share for gross proceeds of $37,499,995.50 and 2,272,727 pre-paid warrants to purchase 2,272,727 common shares at a purchase price of $16.49 per pre-paid warrant for gross proceeds of approximately $37,477,268.23; for an aggregate gross proceeds of $74,977,263.73 on September 7, 2021. The transaction will involve participation from 667, L.P., a fund managed by Baker Bros. Advisors LP for 165,899 shares and 165,899 pre-paid warrants for gross proceeds of $5,473,008.01 and Baker Brothers Life Sciences, L.P., a fund managed by Baker Bros. Advisors LP for 2,106,828 shares and 2,106,828 pre-paid warrants for gross proceeds of $69,504,255.72. The pre-paid warrants have an exercise price of $0.01 per share, subject to adjustment as set forth in the pre-paid warrants. The pre-paid warrants are immediately exercisable and may be exercised at any time until all of the pre-paid warrants are exercised in full. A holder (together with its affiliates) may not exercise any portion of the pre-paid warrant, as applicable, to the extent that the holder would own more than 4.99% of the company’s outstanding common share immediately after exercise. The closing of the transaction is expected to occur on September 10, 2021, subject to satisfaction of customary closing conditions. This agreement may be terminated and the sale and purchase of the purchased shares and pre-paid warrants may be abandoned if the closing has not occurred on or prior to September 30, 2021. The company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the purchased shares to the purchasers, and the company shall file all necessary tax returns and other documentation with respect to such fees, taxes and duties. All securities issued in the transaction are restricted in nature. The securities issued and sold in connection with the transaction are being offered pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D (“Regulation D”) as promulgated by the SEC under the Securities Act. A Form D filing will be made following the closing of the transaction in accordance with the requirements of Regulation D.

Neutral

bluebird bio, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021

2021-08-27 11:21:00

bluebird bio, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021 . Venue: Washigton, District Of Columbia, United States. Speakers: Mitch B Garber, Head of Quality Services.

Neutral

Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021

2021-08-27 10:55:00

Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021. Venue: Washigton, District Of Columbia, United States.

Neutral

Sickle Cell Advocacy, 8th Annual Sickle Cell Warriors Convention, Aug 25, 2021 through Aug 29, 2021

2021-08-20 12:44:00

Sickle Cell Advocacy, 8th Annual Sickle Cell Warriors Convention, Aug 25, 2021 through Aug 29, 2021.

Neutral

bluebird bio, Inc. Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-28-2021 09:00 AM

2021-08-14 17:42:00

bluebird bio, Inc. Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-28-2021 09:00 AM. Speakers: Beth Gardner, Senior Director Patient Supply US.

Neutral

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021

2021-08-14 15:18:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021.

Neutral

bluebird bio, Inc. to Report Q2, 2021 Results on Aug 09, 2021

2021-08-05 20:05:00

bluebird bio, Inc. announced that they will report Q2, 2021 results on Aug 09, 2021

Neutral

bluebird bio, Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-08-05 20:05:00

bluebird bio, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

bluebird bio, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 12:00 PM

2021-08-05 17:05:00

bluebird bio, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 12:00 PM.

Neutral

bluebird bio, Inc. Presents at Cell & Gene Therapy USA, Sep-28-2021 through Sep-29-2021

2021-08-05 05:40:00

bluebird bio, Inc. Presents at Cell & Gene Therapy USA, Sep-28-2021 through Sep-29-2021. Presentation Date & Speakers: Sep-28-2021, Neary Detrick, Senior Director, Enterprise Data Management & Analytics, Rita Johnson-Greene, VP of Sales and Qualified Treatment Centers (QTCs).

Neutral

Reuters Events, Cell & Gene Therapy USA, Sep 28, 2021 through Sep 29, 2021

2021-08-05 03:58:00

Reuters Events, Cell & Gene Therapy USA, Sep 28, 2021 through Sep 29, 2021.

Positive

Bluebird Bio and National Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

2021-07-28 12:04:00

National Resilience, Inc. (Resilience) and bluebird bio, Inc. announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies. As part of the agreement, Resilience will acquire bluebird’s Research Triangle (bRT) manufacturing facility located in North Carolina and retain all of the more than 100 highly skilled technical staff and administrators currently employed at the site. Resilience will continue to support vector supply for both bluebird bio and 2seventy bio, bluebird’s spin-off oncology cell therapy company that is expected to launch by the end of 2021. The two companies are also finalizing a definitive agreement to establish partner programs that will share expense and revenue for successful commercialized oncology products and in parallel establish a next-generation manufacturing R&D collaboration. The 125,000-square foot facility, located in Durham, North Carolina, is currently manufacturing lentiviral vector (LVV), a critical component for cell and gene therapies. The facility includes drug substance and drug product production suites, quality control testing laboratories and warehousing space as well as additional footprint for future expansion. Resilience will continue to invest in the advancement of new technologies and expand the workforce as part of the company’s mission to build a digitally connected, end-to-end biomanufacturing ecosystem. Upon completion of the acquisition, the Resilience network will include 10 sites in North America with more than 1 million square feet of manufacturing, development, and support space. In consideration for the acquisition of the bRT facility upon the closing of the transaction, bluebird will receive $110 million from Resilience. bluebird and 2seventy will continue to benefit from flexible and guaranteed access to LVV manufacturing for their emerging pipeline programs and the facility will be the primary source of suspension LVV. The two companies plan to collaborate on the next phase of 2seventy’s pipeline, each applying their respective innovations in cell therapy development and manufacturing through a risk-sharing model.

Positive

National Resilience, Inc. agreed to acquire Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) for $110 million.

2021-07-28 00:00:00

National Resilience, Inc. agreed to acquire Research Triangle Manufacturing Facility from bluebird bio, Inc. (NasdaqGS:BLUE) for $110 million on July 28, 2021. Resilience will retain all of the more than 100 highly skilled technical staff and administrators currently employed at the site. In a related transaction, National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies. Resilience will continue to support vector supply for both bluebird bio and 2seventy bio, bluebird’s spin-off oncology cell therapy company that is expected to launch by the end of 2021. The two companies are also finalizing a definitive agreement to establish partner programs that will share expense and revenue for successful commercialized oncology products and in parallel establish a next-generation manufacturing R&D collaboration. Resilience will continue to invest in the advancement of new technologies and expand the workforce as part of the company’s mission to build a digitally connected, end-to-end biomanufacturing ecosystem. Upon completion of the acquisition, the Resilience network will include 10 sites in North America with more than 1 million square feet of manufacturing, development, and support space. The closing of the transaction will be subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the negotiation of certain definitive agreements and other customary closing conditions.

Positive

bluebird bio Receives EC Approval for SKYSONA

2021-07-21 09:00:00

bluebird bio, Inc. announced that the European Commission (EC) has granted marketing authorization of SKYSONA™(elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA)-matched sibling hematopoietic (blood) stem cell (HSC) donor is not available. SKYSONA is the first one-time gene therapy approved in the European Union (EU) to treat CALD, a rare neurodegenerative disease that occurs in childhood and can rapidly lead to progressive, irreversible loss of neurologic function, and death. SKYSONA is a one-time gene therapy custom-designed to treat the underlying cause of the neurologic condition CALD. SKYSONA uses ex vivo transduction with the Lenti-D lentiviral vector (LVV) to add functional copies of the ABCD1 gene into a patient’s own HSCs. The addition of the functional ABCD1 gene allows patients to produce the ALD protein (ALDP), which is thought to facilitate the breakdown of VLCFAs. The expression of ALDP and effect of SKYSONA is expected to be life-long. The goal of treatment with SKYSONA is to stop the progression of CALD and, consequently, preserve as much neurological function as possible, including the preservation of motor function and communication ability. Importantly, with SKYSONA, there is no need for donor HSCs from another person. SKYSONA was reviewed as part of the European Medicines Agency’s Priority Medicines scheme (PRIME) and was previously granted Orphan Medicinal Product status. The marketing authorization is valid in all 27 member states of the EU, as well as Norway, Liechtenstein, and Iceland. The marketing authorization of SKYSONA is supported by efficacy and safety data from the Phase 2/3 Starbeam study (ALD-102). Additionally, the Phase 3 ALD-104 study (N=19; as of October 2020) is ongoing. All patients who completed ALD-102, as well as those who will complete ALD-104, will be asked to participate in a long-term follow-up study (LTF-304). The primary efficacy endpoint of the pivotal ALD-102 study was Major Functional Disabilities (MFD)-free survival, measuring the proportion of patients who did not have any of the six MFDs, were alive, did not receive a second allo-HSCT or rescue cell administration, and had not withdrawn or been lost to follow-up at Month 24. In ALD-102, 32 patients have been treated with SKYSONA and, as of October 2020, 30 of 32 patients were evaluable for follow-up at Month 24. As of the data cutoff date, 90% (27/30) of the patients met the Month 24 MFD-free survival endpoint. As previously reported, two patients withdrew from the study at investigator discretion, and one experienced rapid disease progression early in the study, resulting in MFDs and subsequent death. In ALD-102, 26 of 28 evaluable patients maintained a neurologic function score (NFS) less than or equal to 1 through Month 24, and 24 of those patients had no change in their NFS, which showed maintenance of neurological function in the majority of patients. All patients who completed ALD-102 enrolled for long-term follow-up in the LTF-304 study. SKYSONA showed a durable effect on MFD-free survival, with most patients (26/27, 96.3%) that enrolled in LTF-304 remaining alive and maintaining their MFD-free status through their last follow-up on study. The median duration of follow-up was 3.2 years (38.6 months; min.: 13.4; max.: 82.7) and 14 patients reached at least their Year 5 follow-up visit. One patient enrolled in LTF-304 but refused further follow-up later. The treatment regimen, comprising stem cell mobilization and collection, conditioning, and SKYSONA infusion, had a safety/tolerability profile primarily reflective of the known effects of mobilization/apheresis and conditioning. Adverse reactions attributed to SKYSONA observed in clinical trials include cystitis viral, pancytopenia, and vomiting. There have been no reports of graft-versus-host-disease (GVHD), graft failure or rejection, transplant-related mortality (TRM), or replication competent lentivirus in the 51 patients treated with SKYSONA in clinical studies (ALD-102/LTF-304 and ALD-104). Clonal expansion resulting in clonal predominance has been detected in some patients treated with SKYSONA. While there have been no reports of lentiviral vector-mediated oncogenesis, including myelodysplasia, leukemia, or lymphoma, associated with SKYSONA, there is a potential risk of malignancy after treatment with SKYSONA.

Positive

bluebird bio, Inc. Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent ß-thalassemia and Marketing to Resume in EU

2021-07-09 11:30:00

bluebird bio, Inc. announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable. As of July 9, 2021, bluebird bio has informed the EMA that the company is lifting the voluntary marketing suspension. No cases of hematologic malignancy have been reported in any patient who has received treatment with ZYNTEGLO. However because it is manufactured using the same BB305 lentiviral vector used in LentiGlobin for sickle cell disease (SCD; investigational drug product bb1111), bluebird bio decided to temporarily suspend marketing of ZYNTEGLO while the root cause of the safety events reported earlier this year for LentiGlobin for SCD were investigated by the company and assessed by the PRAC. As previously announced on June 7, 2021, the U.S. Food and Drug Administration (FDA) lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for SCD following the Agency’s review of the data. Betibeglogene autotemcel (beti-cel) is a one-time gene therapy that adds functional copies of a modified form of the ß-globin gene (ßA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once a patient has the ßA-T87Q-globin gene, they have the potential to produce HbAT87Q, which is gene therapy-derived adult hemoglobin (Hb), at levels that may eliminate or significantly reduce the need for transfusions. In studies of beti-cel, transfusion independence (TI) is defined as no longer needing red blood cell transfusions for at least 12 months while maintaining a weighted average Hb of at least 9 g/dL. beti-cel is manufactured using the BB305 lentiviral vector (LVV), a third-generation, self-inactivating LVV. The promoter, a regulatory element of the LVV that controls the expression of the transgene, selected for BB305 is a cellular (non-viral) promoter that drives gene expression only in the erythroid lineage cells (red blood cells and their precursors).

Neutral

bluebird bio, Inc. Presents at MRNA-Based Therapeutics Summit, Jul-13-2021 03:00 PM

2021-07-06 14:18:00

bluebird bio, Inc. Presents at MRNA-Based Therapeutics Summit, Jul-13-2021 03:00 PM. Speakers: Jimmy Chu, Scientist II, mRNA Process Development.

Neutral

Hanson Wade Limited, MRNA-Based Therapeutics Summit, Jul 13, 2021

2021-07-06 13:00:00

Hanson Wade Limited, MRNA-Based Therapeutics Summit, Jul 13, 2021.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Fundamental Summary

At a high level, the metrics from bluebird bio's Q4 financial report release provided many positive indicators. Their positive growth and income factors indicate that bluebird bio is likely to continue to produce impressive results for the foreseeable future, as well. We expect that this positive performance will continue in the coming months, and anticipate that bluebird bio will maintain good momentum even in a challenging environment. We therefore gave bluebird bio a total score of 78 out of 100 and a HOLD recommendation.

bluebird bio reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 1.95 million compared to USD 0.894 million a year ago. Net loss was USD 122.15 million compared to USD 205.81 million a year ago. Basic loss per share from continuing operations was USD 1.66 compared to USD 1.81 a year ago. Diluted loss per share from continuing operations was USD 1.66 compared to USD 1.81 a year ago. Basic loss per share was USD 1.66 compared to USD 3.07 a year ago. Diluted loss per share was USD 1.66 compared to USD 3.07 a year ago.

Business Description

bluebird bio, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio in September 2010. bluebird bio was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Sector Overview

bluebird bio is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. bluebird bio's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 593.8 -55.7% 67
Liabilities 219.5 -53.2% 48
Price to Book 1.9 23.4% 57
Cash & Equivalents 161.2 -60.0% 38
Equity 374.3 -57.0% 42
EBITDA -513.8 32.3% 91
Total Revenues 3.7 -93.2% 99
Parameter Value Change Score
Return on Equity -65.1 9.9% 61
Net Cashflow -167.0 -306.7% 89
Capital Expenditure -14.5 30.4% 93
Asset Turnover 0.0 -90.6% 37
Free Cashflow -9.6 5.3% 77

* All values are TTM

The below chart reflects bluebird bio's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While bluebird bio's peer average final assessment score stands on 58.0, bluebird bio's score is 78.

  •  BLUE
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 40 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 41 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 42 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 43 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 44 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 46 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. bluebird bio's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), bluebird bio's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 4.04
52W Low 2.94
52W High 32.42
5D MA 4.29
50D MA 3.71
200D MA 9.34
MACD 0.17
RSI 14.26
STOCH 71.62

Balance Sheet Analysis

Several numbers from bluebird bio's current balance sheet were concerning, in two areas in particular: Cash & Equivalents and Equity. bluebird bio did a poor job related to managing cash and cash equivalents this period, which stood at 161.2, representing a -60.0% change from the previous filing. This performance is significantly less impressive than its peers and competitors. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 38. Also, bluebird bio published concerning equity metrics for this filing. In the current report, equity stood at 374.3, which represents a -57.0% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.7%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 42. That said, one metric, Assets, stood out as strongly positive. bluebird bio's management was effective in managing the value of the assets on their balance sheet, which now sits at 593.8 and represents a -55.7% change from the previous report. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. The company's asset component, therefore, received a grade of 67. Therefore, it received a cautionary score of 50.

Parameter Value Change Score
Assets 593.8 -55.7% 67
Liabilities 219.5 -53.2% 48
Price to Book 1.9 23.4% 57
Cash & Equivalents 161.2 -60.0% 38
Equity 374.3 -57.0% 42
* All values are TTM

The below chart describes bluebird bio's performance as reflected on its balance sheet with respect to its peers. While bluebird bio received a balance sheet score of 50, the average of its peers stands on 60.0.

  •  BLUE
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Geron Corporation 566.2M 69 72 37 59 62 60 40 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 41 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 42 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 43 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 44 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 46 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

bluebird bio seems to be balancing strong Revenue Efficiency and EBITDA along with an overall impressive positive income statement. bluebird bio did an excellent job managing its revenue efficiency this past period. bluebird bio's revenue efficiency is 3.7 according to the metrics in the current filing, which represents a -93.2% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 12.9%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. As a result, its revenue efficiency earned a score of 99. Also, bluebird bio's management was effective in improving its EBIDTA, which now sits at -513.8 and represents a 32.3% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 23.8%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. The company's EBITDA movement, therefore, received a grade of 91. However, one discouraging result, Return Factors, stood out. Return factors metrics and ratios were disappointing in this report. bluebird bio reported a return on equity (ROE) ratio of -65.1, representing a change of 9.9% from the last report.change of 9.9% from the previous period. This metric might have a 2.9 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Therefore, their return factors component earned a score of 61. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 96.

Parameter Value Change Score
EBITDA -513.8 32.3% 91
Total Revenues 3.7 -93.2% 99
Return on Equity -65.1 9.9% 61
* All values are TTM

The below chart describes bluebird bio's performance as reflected on its income statement with respect to its peers. While bluebird bio received a income statement score of 96 , the average of its peers stands on 61.0.

  •  BLUE
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Geron Corporation 566.2M 89 67 73 78 40 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 41 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 42 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 43 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 44 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 46 1
Precigen, Inc. 299.1M 57 87 59 79 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Capex and Net Cash Flow stand out as the most significant drivers of bluebird bio's cash flow's strength. bluebird bio's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -14.5, which represents a 30.4% change from the last period. This performance is all the more impressive relative to their peers and competitors. Consequently, their CapEx movement received a grade of 93. Also, bluebird bio presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -167.0, which is a change of -306.7% from the last filing. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. The company's net cash flow, therefore, received a grade of 89. On the other hand, Asset Turnover, jumped out as looking problematic. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.0, which represents a -90.6% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 3.2 percent by this parameter. The company's asset turnover metrics seem especially problematic relative to their peers. Therefore, their asset turnover movement earned a score of 37. Because their management is doing an excellent job managing these critical metrics, the cash_flow was given a score of 83.

Parameter Value Change Score
Net Cashflow -167.0 -306.7% 89
Capital Expenditure -14.5 30.4% 93
Asset Turnover 0.0 -90.6% 37
Free Cashflow -9.6 5.3% 77
* All values are TTM

The below chart describes bluebird bio's performance as reflected on its cash flow with respect to its peers. While bluebird bio received a cash flow score of 83, the average of its peers stands on 64.0.

  •  BLUE
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Geron Corporation 566.2M 78 68 49 81 77 40 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 41 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 42 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 43 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 44 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 46 1
Precigen, Inc. 299.1M 82 75 37 85 74 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.